Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia

by Business Wire • 2023/03/22 • 0 Comments

SEATTLE & IRVINE, Calif.--(BUSINESS WIRE)-- #VisusTx--Visus Therapeutics announced it completed enrollment in BRIO-I, a pivotal Phase 3 clinical trial of BRIMOCHOL™ PF for the treatment of presbyopia.

← Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

VIDEO: Continued evaluation important for satisfaction with premium IOLs →

Post navigation